Smart Trade Insights
  • Business
  • Economy
  • Investing
  • Politics
Top Posts
Precious Metals & Critical Minerals Hybrid Investor Conference...
Precious Metals & Critical Minerals Hybrid Investor Conference...
S&P Global: Mining Sector Sees Mixed Q1, Next...
S&P Global: Mining Sector Sees Mixed Q1, Next...
Boeing would avoid guilty plea, prosecution over 737...
Rio Silver Receives Conditional Approval for Acquisition of...
Precious Metals & Critical Minerals Hybrid Investor Conference...
Syntheia Signs Non-Binding LOI for Call Center Acquisition
Allied Critical Metals Announces Corporate Update
Top 5 Canadian Mining Stocks This Week: Foremost...
  • Business
  • Economy
  • Investing
  • Politics

Smart Trade Insights

Business

Lawmakers ask Mark Zuckerberg to show how Facebook, Instagram are addressing illicit drug ads

by admin August 17, 2024
August 17, 2024
Lawmakers ask Mark Zuckerberg to show how Facebook, Instagram are addressing illicit drug ads

A bipartisan group of lawmakers sent Meta CEO Mark Zuckerberg a letter on Thursday expressing concern that the company is failing to prevent illicit drug advertisements from running on its platform.

The House members cited recent reports from The Wall Street Journal and nonprofit Tech Transparency Project, which uncovered a flood of ads on Facebook and Instagram that pointed users to third-party services where they could purchase prescription pills, cocaine and other recreational drugs.

“On March 16, 2024, the Wall Street Journal reported that U.S. federal prosecutors have been investigating Meta for facilitating the sale of illicit drugs,” the lawmakers wrote. “Instead of quickly addressing the issue and fully removing the illicit content, on July 31, 2024, the Wall Street Journal again reported that Meta was ‘“running ads on Facebook and Instagram that steer users to online marketplaces for illegal drugs.’”

Most troubling, they wrote, is that Meta continues to run ads despite the company facing an investigation by U.S. federal prosecutors “for facilitating the sale of illicit drugs.”

The letter’s 19 authors include Reps. Tim Walberg (R-Mich.), Gus Bilirakis (R-Fla.), Kathy Castor (D-Fla.) and Lori Trahan (D-Mass.). They noted that the illicit drug ads were “approved and monetized by Meta” and that they were not hidden on the dark web or private social media pages. Media outlets and researchers could easily find the ads, which contained “contained blatant references to illegal drugs,” while Meta’s internal processes apparently missed them.

“Time and time again we have heard from Meta that users come to your platforms because they like the personalization and experiences you provide, and you use sensitive personal information to direct such personalization through content and advertisements,” the lawmakers wrote. “We in Congress, on multiple occasions, have worked to establish data privacy and security protections for Americans but have, in each instance, been met with friction and opposition from Meta with claims that we would drastically disrupt this personalization you are providing.”

They sent Zuckerberg a list of 15 questions intended to uncover more details about how Meta is addressing the problem, and asked him to respond by Sept. 6.

Meta confirmed receipt of the letter and said it plans to respond. The company shared with CNBC the same statement it gave the Journal for its initial story.

“Drug dealers are criminals who work across platforms and communities, which is why we work with law enforcement to help combat this activity. Our systems are designed to proactively detect and enforce against violating content, and we reject hundreds of thousands of ads for violating our drug policies. We continue to invest resources and further improve our enforcement on this kind of content. Our hearts go out to those suffering from the tragic consequences of this epidemic — it requires all of us to work together to stop it.”

This post appeared first on NBC NEWS

previous post
N.J. Gov. Murphy to appoint former chief of staff to Menendez’s Senate seat
next post
Nasdaq Slumps as CPI Data Aligns with Expectations

You may also like

5 new Uber features you should know —...

May 16, 2025

Disney debuts its latest cruise ship, Treasure, as...

November 21, 2024

Retailers saw a dismal fall quarter. The election...

November 28, 2024

Federal Trade Commission accuses three drug middlemen of...

September 24, 2024

East and Gulf coast ports shut down as...

October 3, 2024

Meta’s head of AI research announces departure

April 2, 2025

As retailers drop DEI programs, Black founders could...

February 15, 2025

Grubhub to pay $25M to settle charges that...

December 19, 2024

Bucking trend, McDonald’s vows no egg surcharges as...

February 27, 2025

Nissan could face cost-cutting ‘carnage’ in Honda merger,...

December 26, 2024

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Precious Metals & Critical Minerals Hybrid Investor Conference Agenda Announced for May 22nd

      May 18, 2025
    • Precious Metals & Critical Minerals Hybrid Investor Conference Agenda Announced for May 22nd

      May 18, 2025
    • S&P Global: Mining Sector Sees Mixed Q1, Next Calls for Copper, Battery Metals and M&A

      May 18, 2025
    • S&P Global: Mining Sector Sees Mixed Q1, Next Calls for Copper, Battery Metals and M&A

      May 18, 2025
    • Boeing would avoid guilty plea, prosecution over 737 Max crashes in possible DOJ deal

      May 18, 2025
    Promotion Image

    banner ads

    Categories

    • Business (671)
    • Economy (829)
    • Investing (2,005)
    • Politics (737)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: smarttradeinsights.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 smarttradeinsights.com | All Rights Reserved